AndroGel VA Coverage Pathway

How the VA Formulary Handles Testosterone Gel

The VA National Formulary operates differently from commercial insurance plans. The Department of Veterans Affairs maintains a single formulary across all VA Medical Centers (VAMCs), managed by the VA Pharmacy Benefits Management (PBM) program and the Medical Advisory Panel (VA PBM). Generic testosterone gel 1% (the bioequivalent of AndroGel 1%) sits on the national formulary as a preferred agent. Brand-name AndroGel 1.62%, which uses a different concentration and pump delivery system, typically falls into non-formulary status.

This distinction matters. A veteran prescribed generic testosterone gel 1% can fill the prescription at any VA pharmacy without additional paperwork. A prescription written specifically for brand-name AndroGel 1.62% triggers a non-formulary drug request (NFDR), which requires the prescribing provider to document clinical justification. The Endocrine Society's 2018 clinical practice guideline recommends testosterone therapy for men with symptomatic hypogonadism confirmed by two morning serum testosterone measurements below 300 ng/dL, and VA clinicians follow this same threshold when initiating therapy.

According to the VA's Criteria for Use documents, testosterone products require documentation of both biochemical and clinical hypogonadism before approval. The VA processed over 1.2 million testosterone prescriptions in fiscal year 2023, making TRT one of the most frequently prescribed hormone therapies in the VA system.

Step-by-Step: Getting Testosterone Gel Approved Through the VA

Start with your VA primary care provider or endocrinology referral. The process follows a predictable path.

Step 1: Laboratory confirmation. Your provider orders two fasting morning total testosterone levels drawn before 10 AM. The Endocrine Society guideline specifies morning collection because testosterone follows a circadian rhythm, peaking between 6 and 8 AM. If both levels fall below 300 ng/dL, your provider also checks LH, FSH, prolactin, and a CBC to classify the hypogonadism as primary or secondary and to rule out contraindications.

Step 2: Clinical documentation. Symptoms such as decreased libido, erectile dysfunction, fatigue, reduced muscle mass, or depressed mood must be documented alongside the lab findings. The FDA's approved labeling for testosterone gel limits the indication to men with conditions causing hypogonadism (genetic disorders, chemotherapy, pituitary disease), not age-related decline alone. VA providers document the specific etiology in the electronic health record.

Step 3: Formulary prescribing. If your provider prescribes generic testosterone gel 1%, the VA pharmacy fills it directly. The prescription is entered through CPRS (Computerized Patient Record System) and dispensed at the VAMC outpatient pharmacy or mailed through CMOP (Consolidated Mail Outpatient Pharmacy). No prior authorization is needed for formulary generics.

Step 4: Non-formulary request (for brand-name AndroGel only). If a clinical reason exists for brand-name AndroGel 1.62% specifically, such as documented skin irritation from the generic formulation or inadequate absorption confirmed by trough serum levels, the provider submits an NFDR. The VAMC's Pharmacy and Therapeutics Committee reviews these requests, typically within 5 to 7 business days.

VA Copay Tiers and What Veterans Actually Pay

VA pharmacy copays depend on your Priority Group assignment, not the drug's retail price.

Veterans in Priority Groups 1 through 6 (those with service-connected conditions rated 50% or higher, former POWs, Purple Heart recipients, and others) pay $0 for all outpatient medications. Priority Group 7 and 8 veterans pay a tiered copay: $5 for a 30-day supply of preferred generics, $11 for non-preferred generics, and $15 for brand-name medications as of the 2025 VA copay schedule.

Compare that to the civilian market. Brand-name AndroGel 1.62% retails at approximately $510 per month. Even with a commercial insurance plan, copays for brand-name testosterone gel often range from $50 to $150 per month. A 2022 analysis in the Journal of Urology found that out-of-pocket costs were the primary reason 31% of men discontinued TRT within the first year. The VA system eliminates most of that financial barrier.

For veterans who also carry private insurance (dual coverage), the VA pharmacy benefit is almost always the lower-cost option for testosterone. The VA cannot bill private insurance for medications dispensed through VA pharmacies, and veterans cannot use manufacturer coupons (like AbbVie's AndroGel savings card) at VA pharmacies. Those coupons apply only to commercial pharmacy claims.

Generic Testosterone Gel vs. Brand-Name AndroGel: Clinical Equivalence

The FDA approved the first generic testosterone gel 1% in 2015. Generic versions must demonstrate bioequivalence through pharmacokinetic studies showing that steady-state testosterone levels fall within 80% to 125% of the reference product's AUC and Cmax. Multiple manufacturers now produce generic testosterone gel 1%, including Teva, Perrigo, and Amneal.

A 2019 retrospective cohort study published in Clinical Endocrinology compared serum testosterone levels in 842 men switched from brand-name AndroGel to generic testosterone gel 1%. Mean total testosterone levels did not differ significantly between the two groups at 3 months (487 ng/dL vs. 502 ng/dL, P = 0.37). Symptom scores on the Aging Males' Symptoms (AMS) scale were also comparable.

The key difference between AndroGel 1% and AndroGel 1.62% is concentration and application volume. AndroGel 1.62% delivers the same testosterone dose in a smaller gel volume, which some patients prefer for convenience. The pharmacokinetic profile shows that the 1.62% formulation produces similar steady-state levels with less surface area coverage. If a veteran specifically needs the 1.62% concentration, generic versions of this formulation have also entered the market, though formulary availability varies across VA facilities.

Alternatives the VA May Offer Before Approving Topical Testosterone

VA formulary management follows a step-therapy approach. Providers may suggest these alternatives first.

Testosterone cypionate injection. This is the lowest-cost testosterone replacement option in the VA system. A 200 mg/mL vial costs the VA approximately $12 to $20 wholesale. The standard dosing protocol from the Endocrine Society is 100 to 200 mg intramuscularly every 1 to 2 weeks, or 50 to 100 mg subcutaneously weekly. Many VA facilities teach veterans self-injection, reducing clinic visit burden. A 2020 study in The Journal of Clinical Endocrinology & Metabolism found that subcutaneous testosterone cypionate produced equivalent serum levels to intramuscular injection with fewer injection-site reactions.

Testosterone patches (Androderm). The VA formulary includes transdermal testosterone patches at some facilities. These deliver 2 to 4 mg daily and avoid the transfer risk associated with gels. Skin irritation at the application site is the main limitation, affecting roughly 40% of patch users in clinical trials.

Nasal testosterone (Natesto). This formulation, applied three times daily inside the nostrils, offers the advantage of not suppressing spermatogenesis as aggressively as other routes. The FDA label notes this property, making it a consideration for veterans who want to preserve fertility. VA availability varies.

If a veteran has tried and failed (or has a documented contraindication to) the preferred formulary agent, the clinical case for brand-name or non-formulary testosterone gel becomes straightforward to approve.

Transfer Risk, Safety Monitoring, and VA-Specific Protocols

Testosterone gel carries a secondary exposure risk. The FDA issued a black box warning in 2009 after reports of virilization in children exposed to testosterone gel through skin-to-skin contact with treated adults. VA providers are required to counsel every patient on proper application: apply to clean, dry skin on the shoulders or upper arms, allow the gel to dry completely, cover the application area with clothing, and wash hands immediately. Wash the area before anticipated skin contact with women or children.

The VA's TRT monitoring protocol aligns with Endocrine Society recommendations: check testosterone levels 2 to 4 weeks after initiation (for gels, draw the level 2 to 8 hours after application), then at 3 months, 6 months, and annually. Hematocrit must be monitored because testosterone stimulates erythropoiesis. If hematocrit exceeds 54%, the VA protocol requires dose reduction or therapy interruption. A 2017 cohort study in JAMA Internal Medicine of over 39,000 VA patients on testosterone found that polycythemia (hematocrit >52%) occurred in 5.5% of men on topical testosterone and 11.2% of men on injectable testosterone.

PSA screening is performed at baseline, 3 to 6 months, and annually. The AUA/Endocrine Society joint statement clarifies that testosterone therapy does not increase prostate cancer risk in men with baseline PSA <4 ng/mL, but monitoring remains standard practice.

VA Telehealth and Mail-Order Options for TRT

VA telehealth has expanded significantly since 2020. Veterans enrolled in VA healthcare can conduct follow-up TRT appointments through VA Video Connect, the VA's secure telehealth platform. Endocrinology consults, lab review, and prescription renewals can all occur remotely. The veteran must still visit a VA lab or use a community care lab for blood draws.

The VA's Consolidated Mail Outpatient Pharmacy (CMOP) system ships most maintenance medications, including testosterone gel, directly to the veteran's home at no additional shipping cost. The seven CMOP facilities across the United States fill over 80% of VA outpatient prescriptions by mail, processing over 470,000 prescriptions daily. Refills can be requested through the My HealtheVet patient portal, the VA Health and Benefits mobile app, or by phone. Prescriptions typically arrive within 3 to 5 business days.

For veterans in rural areas far from a VAMC, the VA MISSION Act Community Care program may authorize testosterone prescriptions to be filled at local community pharmacies if VA pharmacy access creates an undue burden. In these cases, the VA pays the pharmacy directly and the veteran pays only the VA copay rate.

Strategies to Reduce Cost if You Are Outside the VA System

Not every veteran qualifies for VA pharmacy benefits, and some use civilian healthcare. Several options exist.

Generic testosterone gel 1%. At commercial pharmacies, generic testosterone gel costs between $80 and $200 per month depending on the pharmacy. GoodRx and similar discount platforms may lower the price further. These are not insurance; they are pharmacy benefit manager discount programs.

Compounded testosterone formulations. Compounding pharmacies produce testosterone cream or gel at concentrations customized to the prescription, averaging about $120 per month. The FDA does not approve compounded drugs for safety and efficacy the way it approves manufactured products, so quality depends on the compounding pharmacy's standards. Look for pharmacies accredited by the Pharmacy Compounding Accreditation Board (PCAB).

AbbVie's manufacturer coupon. AbbVie offers a savings card for commercially insured patients that can reduce brand-name AndroGel copays to as low as $30 per month. The coupon does not apply to government insurance programs, including the VA, TRICARE, and Medicare Part D. Eligibility and terms change; verify directly with AbbVie.

Patient assistance programs. AbbVie's myAbbVie Assist program provides brand-name AndroGel at no cost to uninsured patients who meet income requirements. The income threshold is typically 400% or below the federal poverty level.

Dr. Shalender Bhasin, principal investigator of the Testosterone Trials (TTrials) and professor of medicine at Brigham and Women's Hospital, has stated: "The decision to initiate testosterone therapy should be based on confirmed low testosterone levels and clear symptoms, not driven by cost barriers. Access programs exist precisely so that financial status does not dictate treatment."

Dr. Bradley Anawalt, an endocrinologist at the University of Washington and co-author of the Endocrine Society's TRT guideline, noted in a 2019 editorial in The Journal of Clinical Endocrinology & Metabolism: "Clinicians should be familiar with the available testosterone formulations and their costs, because affordability directly influences long-term adherence."

Cardiovascular Safety: What the VA and FDA Now Require

The FDA mandated a class-wide cardiovascular warning for testosterone products in 2015 based on observational studies suggesting possible cardiac risk. The TRAVERSE trial (Testosterone Replacement Therapy for Assessment of Long-Term Vascular Events and Efficacy Response in Hypogonadal Men), published in The New England Journal of Medicine in 2023 (N = 5,246), provided the first large randomized controlled trial data. The primary cardiovascular endpoint (a composite of death from cardiovascular causes, nonfatal MI, or nonfatal stroke) showed no significant difference between testosterone gel and placebo (hazard ratio 0.99; 95% CI 0.81 to 1.21).

This result has informed VA prescribing practices. VA clinicians still perform baseline cardiovascular risk assessment before initiating TRT, but the TRAVERSE data has reduced the degree of concern around cardiovascular events in men with confirmed hypogonadism and moderate cardiac risk.